Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour — Philippe A. Cassier (2020) | RDL Network
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
Article 2020 en
Authors
PC
Philippe A. Cassier
AI
Antoîne Italiano
CG
Carlos Gomez‐Roca
Abstract
1 min read
Systemic therapy of dTGCT patients with emactuzumab resulted in pronounced and durable responses associated with symptomatic improvement and a manageable safety profile.
Hans Gelderblom, Emanuela Palmerini, Jean Yves Blay, Michiel A. J. van de Sande, Javier Martín‐Broto, Raúl Terés, M. B. Davies, Elyse Seltzer, S. Veltkamp, Gabriel Tinoco
Mehdi Brahmi, Philippe A. Cassier, Armelle Dufresne, Sylvie Chabaud, Marie Karanian, Alexandra Meurgey, Amine Bouhamama, F. Gouin, Gualter Vaz, Jérôme Garret, Marie‐Pierre Sunyach, Aurélien Dupré, Perrine Marec‐Bérard, Nadège Corradini, David Pérol, Isabelle Ray‐Coquard, Jean Yves Blay
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom
Discussion(0)
No comments yet. Be the first to comment.